Under construction – not a live service
Sign in
Not yet taking people in DenmarkNo phase

Examination of Rectal Blood Supply During Rectal Cancer Surgery Using Laser Speckle Contrast Imaging

Key facts

Where
Herning and Vejle, DenmarkSee the 2 sites

Where in Denmark

  • Regional Hospital GødstrupHerning, DenmarkNo longer taking part
  • Sygehus Lillebælt, Vejle HospitalVejle, DenmarkNo longer taking part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
University of Aarhus
Trial code
NCT07799740
Record updated
11 September 2026
Original description
This multicentre feasibility study evaluates the feasibility of performing laparoscopic Laser Speckle Contrast Imaging (LSCI) measurements of rectal perfusion during rectal cancer surgery. To our knowledge, LSCI has not previously been applied laparoscopically for intraoperative assessment of rectal perfusion in this setting. Laparoscopic LSCI measurements will be compared with indocyanine green fluorescence imaging, and associations between quantitative measures of colorectal perfusion and postoperative outcomes, including anastomotic leakage, will be explored.Read full original descriptionShow less

Laser Speckle Contrast Imaging for Rectal Anastomotic Evaluation (LIRA): A Feasibility Study.

This multicentre feasibility study evaluates the feasibility of performing laparoscopic Laser Speckle Contrast Imaging (LSCI) measurements of rectal perfusion during rectal cancer surgery. To our knowledge, LSCI has not previously been applied laparoscopically for intraoperative assessment of rectal perfusion in this setting. Laparoscopic LSCI measurements will be compared with indocyanine green fluorescence imaging, and associations between quantitative measures of colorectal perfusion and postoperative outcomes, including anastomotic leakage, will be explored.

Inclusion: Age ≥ 18 years; Rectal cancer; Surgical strategy either partial or total mesorectal excision; Able to provide informed consent.

Exclusion: Allergy to iodine.

ClinicalTrials.gov NCT07799740